Effect of long-term proton pump inhibitor therapy and healing effect of irsogladine on nonsteroidal anti-inflammatory drug-induced small-intestinal lesions in healthy volunteers
-
- Kojima Yuichi
- Second Department of Internal Medicine, Osaka Medical College
-
- Takeuchi Toshihisa
- Second Department of Internal Medicine, Osaka Medical College
-
- Ota Kazuhiro
- Second Department of Internal Medicine, Osaka Medical College
-
- Harada Satoshi
- Second Department of Internal Medicine, Osaka Medical College
-
- Edogawa Shoko
- Second Department of Internal Medicine, Osaka Medical College
-
- Narabayashi Ken
- Second Department of Internal Medicine, Osaka Medical College
-
- Nouda Sadaharu
- Second Department of Internal Medicine, Osaka Medical College
-
- Okada Toshihiko
- Second Department of Internal Medicine, Osaka Medical College
-
- Kakimoto Kazuki
- Second Department of Internal Medicine, Osaka Medical College
-
- Kuramoto Takanori
- Second Department of Internal Medicine, Osaka Medical College
-
- Inoue Takuya
- Second Department of Internal Medicine, Osaka Medical College
-
- Higuchi Kazuhide
- Second Department of Internal Medicine, Osaka Medical College
Search this article
Abstract
This study assessed time-course changes of the small intestinal lesions during long-term treatment with diclofenac sodium plus omeprazole and the effects of irsogladine on such lesions. Thirty two healthy volunteers were treated with diclofenac sodium (75 mg/day) plus omeprazole (10 mg/day) for 6 weeks, with irsogladine (4 mg/day) added from weeks 6 to 10 (Group A) or with diclofenac sodium plus irsogladine for 6 weeks (Group B). Five volunteers received diclofenac sodium plus omeprazole for 10 weeks (Group C). Subjects underwent capsule endoscopy at each time. In Group A, the number of lesions remarkably increased at week 2, but the worse was not found at week 6 compared with week 2, whereas no exacerbation of lesions was observed in Group B. Additional treatment with irsogladine from weeks 6 to 10 in Group A significantly decreased the number of lesions at weeks 10 compared with Group C. In Group C, no significant change in lesions was observed since weeks 2. In conclusions, a PPI did not prevent the occurrence of small intestinal damage. However such lesions were not aggravated since weeks 2. These suggested mucosal adaptation may occur in the small intestine. Irsogladine was effective in both preventing and healing such lesions.
Journal
-
- Journal of Clinical Biochemistry and Nutrition
-
Journal of Clinical Biochemistry and Nutrition 57 (1), 60-65, 2015
SOCIETY FOR FREE RADICAL RESEARCH JAPAN
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204671455488
-
- NII Article ID
- 130005085263
-
- ISSN
- 18805086
- 09120009
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed